BioSpace News Archive

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its clinical pipeline and other corporate developments.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for 2023.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, announced that it has commenced an underwritten public offering of shares of its common stock.

Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1.

Verily, an Alphabet company focused on precision health, announced the appointment of Utpal Koppikar as Chief Financial Officer.

Assertio Holdings, Inc. today announced that Dan Peisert, CEO, and Paul Schwichtenberg, CFO, will host investor meetings February 15, 2023 as part of the SVB Securities Global Biopharma Conference, taking place virtually.

Fortress Biotech, Inc. today announced that it has entered into definitive agreements for the issuance and sale of 16.6 million shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Galmed Pharmaceuticals Ltd. today that the United States Patent and Trademark Office (USPTO) granted Galmed United States Patent 11,571,431 B2, which is expected to provide exclusivity of Aramchol meglumine salt until December 2034.

Lunit, in conjunction with Agfa HealthCare, announced the successful ‘GO LIVE’ of the breast imaging AI solution, Breast AI Analysis Package, at Dubai Academic Health Corporation Dubai Hospital.